Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SG-ICG
- Development stage
- Unknown
- Lead developer
- Xiamen University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SG-ICG (also known as ICG-SG) is a near-infrared-II (NIR-II) fluorescent molecular imaging probe developed by Xiamen University and Xiang'an Hospital of Xiamen University. It is synthesized by conjugating the near-infrared dye indocyanine green (ICG) to sacituzumab govitecan (SG), a monoclonal antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2). SG-ICG is designed for rapid intraoperative incubation and imaging of freshly resected breast tissues during breast-conserving surgery. By specifically binding to TROP2, which is highly expressed in breast cancer cells, the probe enables real-time, high-contrast visualization of tumor margins and boundaries, helping surgeons ensure complete tumor resection and reduce the need for secondary operations.
- Other names
- indocyanine green-conjugated sacituzumab govitecanindocyanine green-sacituzumab govitecanindocyanine green-sacituzumab govitecan-hziy
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on SG-ICG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SG-ICG.